Trial Profile
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 25 Sep 2023
Price :
$35
*
At a glance
- Drugs Selinexor (Primary)
- Indications Liposarcoma
- Focus Registrational; Therapeutic Use
- Acronyms SEAL
- Sponsors Karyopharm Therapeutics
- 05 Jan 2023 Status changed from active, no longer recruiting to completed.
- 04 Jul 2022 This trial is completed in Belgium(End date;2021-10-26), according to European Clinical Trials Database record.
- 08 Apr 2022 Results published in the Journal of Clinical Oncology